Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Oral Elacestrant vs. Standard-of-Care in ER+/HER2- Advanced or mBC Without Detectable ESR1 Mutation (EMERALD) - Subgroup Analysis by Prior Duration of CDK4/6i + ET"
Comments 0
Login to view comments.
Click here to Login
